H.C. Wainwright raised the firm’s price target on MediWound to $26 from $23 and keeps a Buy rating on the shares after the company’s partner Vericel (VCEL) announced that FDA-cleared NexoBrid is available for commercial launch in the U.S. The firm projects NexoBrid-related royalty revenue to grow to approximately $23M in 2030 from $481,000 in 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDWD:
- MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
- MediWound announces participation at 20th EBA
- MediWound price target lowered to $36 from $63 at Oppenheimer
- MediWound enters research collaboration agreement with MiMedx
- MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
